Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | CDK2 | P24941 | 8/20 | 0.47 |
| ▸ | CDK4 | P11802 | 4/20 | 0.47 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.47 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.47 |
| ▸ | PIM1 | P11309 | 1/20 | 0.47 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16740355 | 0.88 | PKM (0.51) | PKMCDK2KDM4EALDH1A1LMNA | |
| SCHEMBL16740357 | 0.88 | PKM (0.46) | PKMCDK2CDK4CCNE1KDM4E | |
| SCHEMBL18100930 | 0.88 | CDK2 (0.46) | PKMCDK2CDK4CCNE1KDM4E | |
| SCHEMBL18100961 | 0.87 | BRAF (0.46) | PKMCDK2CDK4CCNE1KDM4E | |
| SCHEMBL18100937 | 0.87 | CDK2 (0.52) | PKMCDK2CDK4CCNE1KDM4E | |
| SCHEMBL18100927 | 0.86 | CDK2 (0.50) | CDK2CDK4CCNE1KDM4EALDH1A1 | |
| SCHEMBL18100913 | 0.85 | KDM4E (0.43) | CDK2CDK4CCNE1KDM4EALDH1A1 | |
| SCHEMBL16747812 | 0.85 | PKM (0.44) | PKMCDK2CDK4CCNE1KDM4E | |
| SCHEMBL16747865 | 0.85 | PKM (0.46) | PKMCDK2CDK4CCNE1CSNK1D | |
| SCHEMBL16739776 | 0.85 | PKM (0.46) | PKMCDK2PRKD3MAP4K4PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10584115-B2 | Substituted pyridine and pyrazine BMI-1 inhibitors | PTC THERAPEUTICS, INC. (US) | 2020-03-10 | — | — | US | claimed |
| US-10584115-B2 | Substituted pyridine and pyrazine BMI-1 inhibitors | PTC THERAPEUTICS, INC. (US) | 2020-03-10 | — | — | US | disclosed |
| US-20160280685-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS | PTC THERAPEUTICS, INC. | 2016-09-29 | — | — | US | disclosed |
| US-20160280685-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS | PTC THERAPEUTICS, INC. | 2016-09-29 | — | — | US | disclosed |
| US-20160280685-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS | PTC THERAPEUTICS, INC. | 2016-09-29 | — | — | US | disclosed |
| WO-2015076800-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS | PTC THERAPEUTICS, INC. (US) | 2015-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160280685-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS | BMI1, BAZ2A, BAZ2B | PKM 4004/4885CDK2 1415/4885CDK4 1151/4885 |
| US-10584115-B2 | Substituted pyridine and pyrazine BMI-1 inhibitors | BMI1, BAZ2A, BAZ2B | PKM 4004/4885CDK2 1415/4885CDK4 1151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.